---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-24-000063"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:58:27.498505+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q2 2024 net loss $5.2M; FDA places clinical hold on cadisegliatin T1D trial

## Summary
- Net loss $5.2M ($0.81/sh) vs $5.6M ($2.69/sh) in Q2 2023; cash $45.5M up from $9.4M year-end.
- FDA placed clinical hold on cadisegliatin T1D program in July; no patients dosed in pivotal trial.
- Expanded HPP737 license with Newsoara to global license contingent on $20M upfront fee.
- Cantex received Orphan Drug Designation for azeliragon in pancreatic cancer.
- R&D expenses decreased to $3.4M from $4.7M; G&A increased to $3.7M from $3.3M.

## SEC filing metadata
- accession: 0001641489-24-000063
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000063/0001641489-24-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000063/vtvt-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-24-000063
- JSON: https://secwatch.observer/filing/0001641489-24-000063.json
- Plain text: https://secwatch.observer/filing/0001641489-24-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.